Literature DB >> 17401427

Interactions of mutant p53 with DNA: guilt by association.

E Kim1, W Deppert.   

Abstract

Since the very early days of p53 research, the gain of oncogenic activities by some mutant p53 proteins had been suspected as an important factor contributing to cancer progression. Considerable progress towards understanding the biology of mutant p53 has been made during the last years, the quintessence being the realization that the impact of mutant p53 proteins on the transcriptome of a tumor cell is much more global than previously thought. The emerging role of mutant p53 proteins in coordinating oncogenic signaling and chromatin modifying activities reveals an until now unsuspected function of these proteins as important modifiers of the oncogenic transcriptional response. Notwithstanding the fact that the sequence-specific DNA binding activity of mutant p53 proteins is impaired, they are still able to associate with specific loci on DNA by utilizing different mechanisms. The ability to associate with DNA appears to be crucial for the master role of mutant p53 proteins in coordinating oncogenic transcriptional responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401427     DOI: 10.1038/sj.onc.1210312

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

2.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

3.  Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

Authors:  Gu Xiao; George K Annor; Kimberly Fung; Outi Keinänen; Brian M Zeglis; Jill Bargonetti
Journal:  Mol Pharm       Date:  2020-12-08       Impact factor: 4.939

4.  Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Authors:  Jorge Cortes; Hagop Kantarjian; Edward D Ball; John Dipersio; Jonathan E Kolitz; Hugo F Fernandez; Mark Goodman; Gautam Borthakur; Maria R Baer; Meir Wetzler
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

Review 5.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

6.  Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.

Authors:  Ragu Kanagasabai; Karthikeyan Krishnamurthy; Lawrence J Druhan; Govindasamy Ilangovan
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

8.  Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  Anti-apoptotic NF-κB and "gain of function" mutp53 in concert act pro-apoptotic in response to UVB+IL-1 via enhanced TNF production.

Authors:  Ines Müller; Stefan Beissert; Dagmar Kulms
Journal:  J Invest Dermatol       Date:  2014-11-07       Impact factor: 8.551

10.  Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.

Authors:  Marie Brázdová; Lucie Navrátilová; Vlastimil Tichý; Kateřina Němcová; Matej Lexa; Roman Hrstka; Petr Pečinka; Matej Adámik; Borivoj Vojtesek; Emil Paleček; Wolfgang Deppert; Miroslav Fojta
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.